City Therapeutics (NASDAQ:CTY) Coverage Initiated by Analysts at Stifel Nicolaus

Posted by Kim Johansen on Nov 10th, 2026

Equities research analysts at Stifel Nicolaus started coverage on shares of City Therapeutics (NASDAQ:CTY – Get Free Report) in a research note issued on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $34.00 price target on the stock. Stifel Nicolaus‘s price objective would suggest a potential upside of 82.11% from the stock’s previous close.

CTY has been the subject of a number of other reports. Wall Street Zen upgraded City Therapeutics to a “hold” rating in a research note on Saturday, October 24th. Oppenheimer began coverage on shares of City Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $46.00 price objective on the stock. Jefferies Financial Group assumed coverage on shares of City Therapeutics in a research report on Tuesday. They set a “buy” rating and a $32.00 target price for the company. Finally, The Goldman Sachs Group started coverage on shares of City Therapeutics in a report on Tuesday. They set an “early-stage biotech” rating for the company. Three research analysts have rated the stock with a Buy rating. According to MarketBeat.com, City Therapeutics currently has an average rating of “Buy” and an average price target of $37.33.

Read Our Latest Stock Analysis on City Therapeutics

City Therapeutics Price Performance

City Therapeutics stock opened at $18.67 on Tuesday. City Therapeutics has a one year low of $15.81 and a one year high of $23.88.

Insider Activity

In other news, Director Robert Nelsen bought 170,000 shares of City Therapeutics stock in a transaction that occurred on Monday, October 19th. The stock was bought at an average cost of $18.00 per share, with a total value of $3,060,000.00. Following the acquisition, the director owned 13,692,507 shares of the company’s stock, valued at $246,465,126. The trade was a 1.26% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Arch Venture Partners Xii, Llc bought 170,000 shares of the firm’s stock in a transaction on Monday, October 19th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $3,060,000.00. Following the purchase, the insider owned 13,692,507 shares in the company, valued at $246,465,126. This trade represents a 1.26% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.